TG Therapeutics
TGTX
67 hedge funds and large institutions have $122M invested in TG Therapeutics in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 2 closing their positions.
800% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 2
680% more call options, than puts
Call options by funds: $7.49M | Put options by funds: $960K
52% more capital invested
Capital invested by funds: $80.3M → $122M (+$41.6M)
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
31% more funds holding
Funds holding: 51 → 67 (+16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$4.03M |
| 2 |
Millennium Management
New York
|
+$1.73M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.07M |
| 4 |
CCI
Columbus Circle Investors
|
+$1.02M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$899K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.52M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$895K |
| 3 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$721K |
| 4 |
Morgan Stanley
New York
|
-$592K |
| 5 |
Jennison Associates
New York
|
-$307K |
TGTX Hedge Fund Activity: Q2 2014 in Review
67 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2014, worth a combined $122M — up 52% from $80.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TGTX positions and 2 closed out — a net gain of 16 holders — while 25 added to existing stakes and 19 trimmed.
The largest buyer was Visium Asset Management, opening a new position worth an estimated $4.03M. The largest seller was JP Morgan Chase, cutting an estimated $3.52M.
- 67 institutional investors held TG Therapeutics (TGTX) as of Q2 2014, up from 51 in Q1 2014.
- Funds reported $122M of TG Therapeutics stock for Q2 2014, up 52% quarter-over-quarter.
- 18 funds opened new TG Therapeutics positions in Q2 2014 and 2 closed out, a net change of +16 holders.
- The largest TG Therapeutics buyer in Q2 2014 was Visium Asset Management, an estimated $4.03M added.
- The largest TG Therapeutics seller in Q2 2014 was JP Morgan Chase, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2014.